drugset / Trial / NCT03365635

Administration of Zepatier (Grazoprevir Plus Elbasvir) in Chronic Hemodialysis (HD) Patients With Hepatitis C

NCT03365635

Non-randomizedSingle-groupOpen-labelTreatment

Summary

This is a study to define strategies for Nephrologists to directly supervise and apply direct acting antivirals to cure hepatitis C in hemodialysis patients. Strategies will include identification of candidate patients, application for insurance approval, specifics of direct acting antiviral therapy (Zepatier with or without ribavirin) and laboratory monitoring during and after therapy.

Timeline

Start
2019-09-22
Primary completion
2020-05-01
Completion
2020-09-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Elbasvir Small molecule 50 mg Oral
Subject GRAZOPREVIR ANHYDROUS Small molecule 100 mg Oral
Subject Ribavirin Small molecule 200 mg Oral